Lung cancer therapy is 'milestone'
A lung cancer therapy can more than double life expectancy in some patients, a "milestone" trial shows. Nivolumab stops cancerous cells hiding from the body's own defences, leaving the cancer vulnerable to attack. The results from 582 people, presented at the American Society of Clinical Oncology, were described as "giving real hope to patients".
No comments:
Post a Comment